Panel Discussion: Women Rising: How to Elevate Women in Leadership Roles
Margaret Scott
Vice President, Genentech
For more than 45 years, Genentech has been following the science, seeking solutions to unmet medical needs. As a proud member of the Roche Group, we make medicines to treat patients with serious medical conditions.
We are headquartered in South San Francisco, California.
Dr. Margaret Porter Scott is Vice President of Biochemical and Cellular Pharmacology at Genentech. She and her team bring expertise in quantitative in vitro assays and the mechanistic study of molecules to all of Genentech’s research programs across all therapeutic areas and all modalities. Previous to joining Genentech, Margaret was the first employee of Epizyme rising to Senior Director of Lead Discovery, and was instrumental in delivering several first-in-human inhibitors including the approved drug Tazemetostat for the treatment of epithelioid sarcoma. Prior to Epizyme, Margaret had over a decade of training in drug discovery through her scientific positions at Millennium, Neogenesis, Vertex, and Pfizer. Margaret received her BA from Oberlin College and her Ph.D. from SUNY Stony Brook.